Macchia E, Agostini M, Sarkissian G, Giorgilli G, Canale D, Scartabelli G, Margotat A, Torresani J, Pinchera A
Istituto di Endocrinologia, Università di Pisa, Italy.
J Endocrinol Invest. 1998 Apr;21(4):226-33. doi: 10.1007/BF03347307.
Resistance to thyroid hormone (RTH) is almost invariably associated with mutations of the thyroid hormone (TH) receptor beta (hTR beta) gene and is inherited as an autosomal dominant disease. Mutations of hTR beta identified in patients affected by RTH cluster generally at two spots of the ligand binding domain. We investigated whether an Italian kindred with RTH had a mutation in the thyroid hormone (TH) receptor beta gene. Blood samples were obtained from the available family members for biochemical and genetic analyses. Thyroid function tests in basal conditions, and in the case of the propositus also following incremental doses of T3, were performed. Exon 4 to 10 of hTR beta gene were amplified using the polymerase chain reaction (PCR) and the mutation was identified by direct sequence analysis. The affinity constant of this mutated receptor for T3 was measured by in vitro transcription-translation and was then compared with that of wild type. We identified a heterozygous G to A transition at nucleotide 1037 of exon 8 at codon 251, resulting in a glycine (G) to glutamic acid (E) substitution (G251E) in the patient affected by RTH and in his affected offspring, but not in the normal family members. This novel mutation represents a de novo mutation since both parents of the index case were unaffected and did not have this genomic mutation. When expressed in vitro, the mutant protein (G251E) showed a marked decrease of the affinity for T3, suggesting an impaired ligand-dependent transactivation activity of this mutant receptor. In vivo studies with incremental doses of L-T3 demonstrated a reduced sensitivity to TH in the index case, in particular at the pituitary level where the thyrotrophs' activity was not completely inhibited even by 200 micrograms/day of L-T3. G251E mutation represents the fourth mutation described up to now in exon 8 of hTR beta among the subjects affected by RTH. A third cluster of mutations of the c-erbA beta gene located proximally with respect to the other two so far described begins to emerge in RTH patients.
甲状腺激素抵抗(RTH)几乎总是与甲状腺激素(TH)受体β(hTRβ)基因的突变相关,并且作为常染色体显性疾病遗传。在受RTH影响的患者中鉴定出的hTRβ突变通常聚集在配体结合域的两个位点。我们调查了一个患有RTH的意大利家族是否存在甲状腺激素(TH)受体β基因突变。从现有的家庭成员中采集血样进行生化和基因分析。进行了基础状态下的甲状腺功能测试,对于先证者,还进行了递增剂量T3后的测试。使用聚合酶链反应(PCR)扩增hTRβ基因的第4至10外显子,并通过直接序列分析鉴定突变。通过体外转录-翻译测量该突变受体对T3的亲和常数,然后与野生型进行比较。我们在第8外显子第251密码子的核苷酸1037处鉴定出一个杂合的G到A转换,导致受RTH影响的患者及其受影响的后代中甘氨酸(G)被谷氨酸(E)取代(G251E),但正常家庭成员中没有。这种新突变代表了一个新发突变,因为索引病例的双亲均未受影响且没有这种基因组突变。当在体外表达时,突变蛋白(G251E)对T3的亲和力显著降低,表明该突变受体的配体依赖性反式激活活性受损。用递增剂量的L-T3进行的体内研究表明,索引病例对TH的敏感性降低,特别是在垂体水平,即使每天给予20 μg的L-T3,促甲状腺细胞的活性也未被完全抑制。G251E突变是迄今为止在受RTH影响的个体中hTRβ第8外显子中描述的第四个突变。相对于迄今为止描述的另外两个突变,位于近端的c-erbAβ基因的第三组突变开始在RTH患者中出现。